1. Centre for Cancer Research
  2. Our Research
  3. Precision Oncology
  4. Illumina-University of Melbourne Partnership

Illumina-University of Melbourne Partnership

Partnering to provide the infrastructure, expertise, systems and analysis to translate and implement genomics into routine clinical care.

Subscribe

HomePlatformsProjectsAboutContact
Partnership team

Genomics-driven personalised care presents an incredible opportunity to transform patient outcomes and create substantial efficiencies for the healthcare system.

Illumina and the University of Melbourne are partnering affordable, scaleable next-generation sequencing with the research expertise, infrastructure, systems and analysis needed to implement genomics into routine clinical care.

Based in the Melbourne Biomedical Precinct, our collaborative, cross-disciplinary approach translates evidence-based advancements into the clinic, supporting local training and jobs.​

The Illumina-University of Melbourne partnership will lift local genomics research and clinical trials to a global scale and quality, driving collaboration within the Precinct through the development of three core enabling platforms in clinical genomics, bioinformatics, and health economics.

Announcing The Illumina-University of Melbourne Genomics Hub

Illumina and University of Melbourne, together with Invest Victoria, are excited to launch The Illumina-University of Melbourne Genomics Hub. Find out more about how the Hub will become a key driver in building workforces and businesses of the future, delivering first-hand, practical experience and fostering a pipeline of commercially focused genomics innovation projects.

The core enabling platforms

The establishment of three core enabling platforms is vital to fostering a pipeline of commercially focused genomic innovation projects. Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. The platforms will be underpinned by cloud-based informatics infrastructure enabling the delivery of genomics at scale for flagship and future innovation projects.

  • Clinical Genomics Platform

    Expanding the patient sequencing capacity of the Melbourne Biomedical Precinct.

  • Bioinformatics Platform

    Building the infrastructure and personnel to rapidly analyse large datasets of patient genomic information.

  • Health Economics Platform

    Enabling rapid translation of genomics into health services through treatment modelling to highlight improved clinical results and economic benefits.

Flagship research programs

Researchers from the University of Melbourne and Peter Doherty Institute are leading the first flagship genomic innovation projects, leading the way for the future pipeline of commercially focused genomics innovation projects to utilise the partnership's infrastructure and expertise.

  • Cancer of Low Survival and Unmet Need Initiative

    Sequencing genomes of the most challenging cancer cases in real-time for personalised clinical treatment and care.

  • ID Predict: A genomics-focused platform for treatment of COVID-19 and other infectious diseases

    Genomics platform to understand the varied types of disease progression of patients with COVID-19, which will help to identify what treatment is best suited to individual patients.

  • Cancer Liquid Biopsy: Non-invasive blood-based monitoring for cancer

    Using genomic tools for detection and monitoring of circulating tumour DNA (ctDNA) in patient blood samples to enable cancer detection, surveillance and recurrence screening

Latest news

  • Genomics innovation hub to drive research and clinical impact

    The University of Melbourne, together with international genomics company, Illumina, have welcomed the Victorian Government’s support to establish a $60 million world-leading genomics hub in Victoria.

    04 Dec 2020 News
  • The Genomic Jigsaw of Cancer

    Mapping the human genome is revolutionising medicine. The aim? To turn cancer into a manageable, chronic disease like diabetes.

    12 Feb 2020 News
  • Patients with challenging cancers to benefit from genomic sequencing

    More than 1000 Victorian cancer patients are set to benefit from real-time genomic testing in the next three years, aiming to improve diagnosis and provide more targeted and effective treatments for cancers of unmet need.

    12 Feb 2020 News
  • The Global Cancer Atlas

    Scientists around the world have collaborated to create the most comprehensive map of whole cancer genomes to date, improving our fundamental understanding of cancer and how to treat it.

    06 Feb 2020 News
  • Illumina partnership to drive genomics innovation in Australia

    The University of Melbourne and Illumina, one of the world’s leading biotech companies, have announced a partnership that will enhance Melbourne’s reputation as a world-class biomedical precinct.

    28 Feb 2019 News

The three core enabling platforms of the Illumina-University of Melbourne partnership are vital to fostering a pipeline of commercially focused genomic innovation projects.

Together with Illumina’s commercial expertise and global connections, the core platforms will enable the Melbourne Biomedical Precinct to capitalise on its competitive advantage in genomics research thanks to our world-leading researchers. The platforms will be underpinned by cloud-based informatics infrastructure enabling the delivery of genomics at scale for flagship and future innovation projects.

  • Bioinformatics Platform

    Building the infrastructure and personnel to rapidly analyse large datasets of patient genomic information.

  • Health Economics Platform

    Enabling rapid translation of genomics into health services through treatment modelling to highlight improved clinical results and economic benefits.

  • Clinical Genomics Platform

    Expanding the patient sequencing capacity of the Melbourne Biomedical Precinct.

Projects enabling the rapid translation of research to quickly and effectively act on health threats such as cancer and infectious disease.

Researchers from the University of Melbourne and Peter Doherty Institute are leading the first flagship genomic innovation projects, leading the way for the future pipeline of commercially focused genomics innovation projects to utilise the partnership's infrastructure and expertise. The Cancer of Low Survival and Unmet Need health systems innovation project aims to improve diagnosis and provide more targeted and effective treatments for cancers of unmet need.

  • Cancer of Low Survival and Unmet Need Initiative

    Sequencing genomes of the most challenging cancer cases in real-time for personalised clinical treatment and care.

  • ID Predict: A genomics-focused platform for treatment of COVID-19 and other infectious diseases

    Genomics platform to understand the varied types of disease progression of patients with COVID-19, which will help to identify what treatment is best suited to individual patients.

  • Cancer Liquid Biopsy: Non-invasive blood-based monitoring for cancer

    Using genomic tools for detection and monitoring of circulating tumour DNA (ctDNA) in patient blood samples to enable cancer detection, surveillance and recurrence screening

Genomics-driven personalised care presents an incredible opportunity to transform patient outcomes and create substantial efficiencies for the healthcare system.

Illumina and the University of Melbourne are partnering affordable, scaleable next-generation sequencing with the research expertise, infrastructure, systems and analysis needed to implement genomics into routine clinical care.

Based in the Melbourne Biomedical Precinct, our collaborative, cross-disciplinary approach translates evidence-based advancements into the clinic, supporting local training and jobs.​

The Illumina-University of Melbourne partnership will lift local genomics research and clinical trials to a global scale and quality, driving collaboration within the Precinct through the development of three core enabling platforms in clinical genomics, bioinformatics, and health economics.

  • The Illumina-University of Melbourne Genomics Hub

    The Illumina UoM Genomics Hub will accelerate the translation and commercialisation of biomedical research into a cluster of high-growth, high-tech startups.

  • The need

    Increasing genomics innovation and its translation and adoption into the healthcare system to improve patient outcomes.

  • Recruitment

    Opportunities to join our core enabling research platforms and programs.

  • People

    The researchers behind the core enabling platforms.

  • What is genomics?

    Genomics is the study of genes and what they do.

Subscribe for updates and get in touch to see how you can be involved.

Media inquiries

Zoe Stephenson
Communications and Public Relations Manager
University of Melbourne Centre for Cancer Research
+61 466 566 004
zoe.stephenson@unimelb.edu.au

Centre for Cancer Research

  • News & Events
    • Is delayed cancer diagnosis a consequence of COVID-19?
    • Cancer Health Services Research group celebrates two-year anniversary
    • Funding to Identify novel therapeutic targets in leukaemia stem cells
    • MRFF grant to predict the population health economic impact of new cancer treatments
    • New research to benefit patients with hard-to-treat cancer of unknown primary
    • What's gone wrong with managing bowel cancer in Australia?
    • Health professionals predict rising challenges for cancer care
    • A health economics perspective on comprehensive genome profiling
    • Caring for the terminally ill in prison
    • Personalising bowel cancer detection
    • 2021 Honours and Masters research opportunities
    • How one misconception means seriously ill people miss out on care
    • A new discovery in regenerative medicine
    • Cancer research embraces a shared vision
    • New study models cost of additional genomic findings
  • Our Research Groups
  • Engage
    • Support
    • Infrastructure
    • Our Collaborators
  • Study
  • About
    • Contact Us
    • People
    • Opportunities
    • About us
  • Flagship Programs
    • Cancer of Low Survival and Unmet Need Initiative
    • SUPER-NEXT: Solving Unknown Primary Cancer
    • Identifying drivers of treatment resistance in metastatic colorectal cancer
    • PRIMCAT: Predicting the population health economic impact of current and new cancer treatments
    • Bowel cancer prevention and early detection in primary care
    • The Care Plus Study: A multi-site implementation of early palliative care in routine practice to improve health outcomes for people with advanced cancer
    • Palliative care provision for people who are prisoners
    • PRostatE CancEr Prognosis and Treatment (PRECEPT)
  • Current Students
  • Library
  • Staff